Longevity & AgingRetatrutide Delivers 28% Weight Loss Rivaling Bariatric Surgery in Late-Stage Trial
Eli Lilly's next-generation obesity drug retatrutide produced an average 28.3% body weight reduction over 80 weeks in a late-stage clinical trial — surpassing current blockbusters like Wegovy and approaching bariatric surgery outcomes. More than 45% of patients lost at least 30% of their body weight, a threshold previously linked only to surgical intervention. The drug works via a weekly injection and appears more tolerable than earlier data suggested, with fewer patients stopping treatment due to side effects. Beyond weight loss, retatrutide has shown promise in reducing knee pain and improving metabolic markers, positioning it as a potential tool for delaying the chronic diseases — cardiovascular disease, diabetes, and joint degeneration — that drive aging and reduce healthspan.
